Novavax Inc (NVAX)
$16.24
0.14 (0.87%)
NVAX Stock Quote Delayed 20 Minutes
Previous Close
$16.10
Market Cap
6.20B
PE Ratio
-26.62
EPS
-0.61
Volume (Avg. Vol.)
12,012
Day's Range
16.10 - 16.10
52-Week Range
0.34 - 17.71
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
How We “Flipped” a Beaten-Down Company for 126% Gains
Investors began buying up NVAX shares in anticipation of the Phase 3 clinical trial announcement. We wound up with a 130% gain on the trade.
Novavax Earnings: NVAX Stock Soars 8% on Strong Q4 Revenue Beat
Novavax (NVAX) earnings for the vaccine company's fiscal fourth quarter of 2019 have NVAX stock heading higher after-hours Wednesday.
Stock Market Today: Turnaround Tuesday; Tesla’s Big Milestone
Tesla made its one-millionth car, while Delta expects to save $2 billion in fuel costs. Here's the stock market today.
Stock Market Today: Coronavirus Stokes Fear; Uber Stock Rallies
Boeing shares tanked on more negative reports, while Uber rallied on an asset sale. Here's what happened in the stock market today.
Novavax News: NVAX Stock Skyrockets 52% on Mystery China Virus
Novavax (NVAX) news for Tuesday concerning the spread of a virus in China has NVAX stock heading higher as more investors pick up the stock.
Novavax News: Why NVAX Stock Is Shooting Higher Today
Novavax news for Thursday concerning an accelerated approval pathway for one of the company's drugs has NVAX stock soaring higher.
Novavax News: Why NVAX Stock Is Plunging Today
Novavax news concerning the results from the company's recent trail of its drug ResVax has NVAX stock falling on Thursday.
Novavax Stock Is a Cautionary Tale for Speculators
Novavax stock is plunging on Thursday after failing a Phase 3 study. That sets up a breakdown instead of a breakout in NVAX stock.
Novavax (NVAX) Stock Upgraded to Buy
As one of the 657 companies in the GICS Health Technology sector Novavax Inc (NASDAQ:NVAX) is a constituent of the 337 company Biotechnology GICS industry group within this sector. NVAX has a market value of $0.6 billion which is in the top half of its industry group. Portfolio Grader's current ranking for NVAX puts it 107 among the 337 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 213 among the 657 companies in the sector, and number 1,498 in the nearly 5,000 company Portfolio Grader universe.
Earnings Visibility Hamper Novavax (NVAX) Rating
Novavax Inc (NASDAQ:NVAX) ranks in the upper half of its industry group, Biotechnology, and in the upper half of its sector group, Health Technology, with a market value of $0.4 billion. From an investment attractiveness vantage point, NVAX is ranked in the top half of the sector with a ranking of 264 among the 656 companies in the sector; the ranking for NVAX by Portfolio Grader places it 127 among the 337 companies in this industry group, giving it an above-average position and number 1,942 in the 5000 company Portfolio Grader company universe.
40 Biotechnology Stocks to Sell Now
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
40 Biotechnology Stocks to Sell Now
The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
